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ABSTRACT 
 
 
Objective: To extend our studies on the glycolipid-reactive invariant Natural Killer T-cell 
(iNKT-cell) function in multiple sclerosis (MS), we investigated the stimulatory activities of two 
myelin-derived glycolipids which are poly-acetylated derivatives of β-galactosylceramide, 
designated PA-GC and FMC-7 (fast migrating cerebroside-7). 
Methods: Peripheral blood mononuclear cells from MS patients or healthy control subjects were 
stimulated with PA-GC, FMC-7 or α-galactosylceramide (α-GalCer). In cell expansion studies, 
the frequencies of iNKT-cells were analysed before and after glycolipid stimulation by flow 
cytometry. Analysis of cytokines in culture supernatants was performed using Th1/Th2 
multiplexing and flow cytometry.  
Results: In healthy subjects, the myelin-derived glycolipids significantly expanded iNKT-cells 
in a similar way to α-GalCer and induced significant increases of Th1, Th2 and Th17 cytokines 
in peripheral blood cultures. In marked contrast, MS patients failed to respond to either of the 
myelin-derived acetylated glycolipids or to α-GalCer stimulation indicating an anergic response. 
Conclusions: We propose that myelin-derived glycolipids stimulate iNKT-cell responses in vivo 
and that regulation or inhibition of this response may determine the immune response or disease 
onset in the CNS. 
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INTRODUCTION 
Invariant Natural Killer T cells (iNKT-cells) express a unique T-cell receptor (TCR) 
encoded by invariant Vα24-Jα18 alpha chain gene segments in humans.1,2,3 iNKT-cells produce 
large amounts of IFN-γ and IL-4 upon activation particularly by α-GalCer,4,5 and have diverse 
effects including regulation of autoimmunity.3,6 Multiple sclerosis (MS) is a demyelinating 
disease affecting the CNS, that is characterized clinically by periods of relapse and remission and 
usually by a progressive course.7 A dysregulated T-cell response to myelin antigens is believed 
to mediate the pathology.8 Previously, we reported alterations in MS of circulating T-cells 
expressing the NK markers CD56 and CD161 and lacking an invariant TCR (NKR+ T-cells). 
Moreover, the iNKT-cells from MS subjects displayed hyporesponsiveness or anergy to α-
GalCer stimulation in vitro.9 Given the lipid-rich nature of myelin the question of whether brain-
derived lipids stimulate iNKT-cells warranted study. Sulfatide is reported to stimulate semi-
invariant T-cells in MS10 but roles for other myelin-derived iNKT-cell ligands in MS have not 
been defined.  
Previously, we characterised a novel mammalian brain glycosphingolipid (GSL) series 
that accounts for 15-35% of total myelin GSL content, and which are designated ‘fast-migrating 
cerebrosides’(FMC) on the basis of TLC migration.11-13 They include simple and more complex 
compounds ranging to penta- and hexa-acetylated derivatives of β-galactosylceramide (i.e. the 
‘cerebrosides’). This study was designed to evaluate glycolipid antigenic specificities of iNKT-
cells in MS by examining the response to GalCer, the most potent activator of iNKT immune 
responses and to two of the myelin-derived acetylated glycolipids, the polyacetylated-β-
galactosylceramides or PA-GC and purified FMC-7.   
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METHODS 
Patient samples 
All of the MS patients studied were diagnosed using standard clinical criteria including MRI 
scanning and CSF examination. Patients were classed as relapsing-remitting MS (RRMS, n = 9), 
secondarily progressive MS (SPMS, n = 3), and primary progressive MS (PPMS, n = 1), and 
ranged from 33-74 years of age (male: female, 1:5), with healthy control subjects (HS, n = 22) 
from 23-50 years (male: female, 1:3.5). In all cases, informed consent was obtained. The subjects 
were studied in a blind-controlled manner. Ethical approval was obtained from the University 
College Hospital Galway Ethics Committee and from the National University of Ireland, Galway 
Research Ethics Committee. 
 
Flow cytometry 
PBMCs were isolated from whole blood by standard Histopaque-1077® (Sigma Chemical Co., 
St. Louis, MO) density gradient centrifugation. Fluorochrome-labelled monoclonal antibodies 
specific for human CD3 (phycoerthyrin-RPE:Cy5), and for the NK markers CD56 (fluorescein 
isothiocyanate-FITC), CD161(FITC) and CD94 (FITC) were obtained from Serotec (Oxford, 
UK). Human invariant V24J18 TCR-chain (PE) was obtained from BD Pharmingen 
(Oxford, UK). The expression of surface antigens on fresh or cultured PBMCs were detected by 
monoclonal antibody staining and two- and three-colour flow cytometry (FACSCalibur® and 
CellQuest® lysis software, Becton Dickinson, Oxford, UK). 
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Glycolipids 
-GalCer was obtained from Alexis Biochemicals (San Diego, USA). It was dissolved in 10% 
dimethylsulfoxide (DMSO) in 1X PBS at a concentration of 1mg/ml, and diluted 1:100 with 
PBMC preparation to the required final concentration of 10μg/ml. The FMC fractions are 
derivatives of β-galactosyl-ceramide purified from the brain. The myelin derived glycolipid 
fractions used here were (1) a mixture of penta- and hexa-acetylated FMCs, FMC-5 and FMC-7 
which is designated polyacetylated-β-galactosylceramide or PA-GC and (2) purified FMC-7 
which has an additional acetylation of the 2-hydroxy-fatty acid. These glycolipids had initially 
been purified to homogeneity and characterized by mass spectrometry.11-13 The PA-GC and 
FMC-7 were dissolved in 1% BSA and diluted in RPMI to a final concentration of 10μg/ml. 
Figure 1 illustrates the structures of FMCs including the purified FMC-7. 
 
In vitro stimulation and expansion studies 
1 x 106 PBMC/ml were suspended in complete RPMI medium (RPMI medium containing 25mM 
HEPES, 2mM L-glutamine, 50 g/ml streptomycin, 50 U/ml penicillin, and 10% foetal calf 
serum) and stimulated for up to168 hours with 10μg/ml of PA-GC, FMC-7, -GalCer or medium 
alone as control. After 7 days in culture, the numbers of iNKT-cells (CD3+Vα24Jα18+), NK cells 
(CD3-CD56+) and NKR+ T cells (CD3+CD56+ or CD3+CD161+ or CD3+CD94+) in stimulated 
and unstimulated cultures were compared using flow cytometry. 
 
Cytokine production 
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The cytokine levels in PBMC culture supernatants were measured at 168 hours after stimulation 
with PA-GC, FMC-7 glycolipid or -GalCer. IL-17 levels were measured using the capture 
ELISA system from R&D Systems, Oxon, UK. The following cytokines were measured using 
the FlowCytomix multiplex kit from BenderMed Systems (Vienna, Austria): IL-1β, IL-2, IL-4, 
IL-5, IL-6, IL-8, IL-10, IL-12 (p70), TNF-, TNF-beta, and IFN-γ. The cytokines were 
measured in the culture supernatants according to the manufacturer’s instructions.  
 
Statistics 
Differences between groups of non-parametric data were analysed using the Mann-Whitney U 
statistic using GraphPad In Stat® software (GraphPad Software Inc); p< 0.05 was considered 
significant. 
 
RESULTS 
Expansion studies 
The expression of the V24J18+TCR alpha chain defines CD1d-restricted iNKT-cell 
populations.1 Previously we reported a significant increase in iNKT-cell numbers in the 
peripheral blood of MS subjects compared with HS, and also that in functional studies iNKT-cell 
reactivity to -GalCer was impaired in MS subjects when compared.9 Reactivity to myelin-
derived acetyl-glycolipid stimulation was investigated here and the results compared to -
GalCer. PBMC were cultured with PA-GC, FMC-7 or -GalCer for 7 days, and after this time 
the proportions of NK cells, NKR+ and iNKT-cells were quantified by flow cytometry. As shown 
in Fig.2: in HS, iNKT-cell numbers significantly expanded in response to stimulation with the 
PA-GC (1.4± 0.4%, p= 0.04) and to purified FMC-7 (2.7± 1.9%, p= 0.02) when compared with 
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unstimulated cells (0.64± 0.4%). In marked contrast to HS, iNKT-cells from MS subjects failed 
to respond to PA-GC (0.85±0.59%, p= 0.60) or to FMC-7 (1.4±0.3%, p= 0.9). As previously 
reported9 stimulation with -GalCer significantly expanded the numbers of iNKT-cells in 
cultures from HS (7.4±1.6%, p = 0.0045) but not in MS subjects (1.6±1.0%, p= 0.38) relative to 
unstimulated cultures. When RRMS, SPMS and PPMS subjects were compared, there were no 
differences observed in responses to PA-GC, FMC-7 or -GalCer stimulation in any of the 
subject groups (data not shown). 
In addition to iNKT-cells, the percentages of NKR+ T-cells (CD3+CD56+, CD3+CD161+ 
and CD3+CD94+) and NK cells (CD3-CD56+ cells) amongst PBMC were determined after 
stimulation with PA-GC, FMC-7 or -GalCer. As shown in Table 1, the numbers of NK cells 
and NKR+ T cells did not change significantly upon stimulation with any of the glycolipids 
tested and this was evident in both the HS and MS subject groups.  
To determine the cytokine production of PBMC, we examined the supernatants of cells 
from HS and MS patients stimulated with the FMC fractions or -GalCer in comparison to 
unstimulated cell cultures (Figure 3). The levels of IL-17 were measured using ELISA while the 
levels of IL-1β, IL-2, IL-4, IL-5, IL-6, IL-10, IL-12 (p70), TNF-, and IFN-γ were determined 
using cytokine multiplexing. 
FMC-7: In HS, IL-17 levels in PBMC cultures were significantly upregulated by stimulation 
with FMC-7 (p=0.03) compared with levels in unstimulated cultures. Likewise, FMC-7 
stimulated significant production of IFN- γ (p=0.008), TNF- (p=0.008), IL-1  (p=0.008) and 
IL-6 (p=0.02) by PBMC from 5 of 7 HS respectively. IL-10 levels were also significantly 
upregulated by stimulation with FMC-7 in PBMC cultures from 4 of 7 HS (p=0.03). Although 
the levels of IL-2, IL-4, IL-5, and IL-12 were increased by stimulation with FMC-7 (ranging 
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from 2-5 of 7 individuals), the levels failed to reach significance. This data indicates that the 
purified FMC-7 glycolipid preparation enhances cytokines associated with Th1 (IFN- γ), Th17 
(TNF-), and both pro-(IL-1 , IL-6, TNF-), and anti-inflammatory responses (IL-10).  
PA-GC: To compare the effects of FMC-7 and PA-GC on PBMCs, cytokine production 
following stimulation experiments with PA-GC was investigated. In HS, IL-17 and IFN-γ levels 
were increased upon stimulation although the levels did not reach significance. PA-GC also 
stimulated IL-2, IL-4, IL-5, IL-6, IL-10, IL-12, IL-1  and TNF-α production by PBMC from HS 
(ranging from 2-5 of 7 subjects) although again the levels did not reach significance. These 
results indicate that unlike purified FMC-7, PA-GC that is a mixture of FMC-5 and FMC-7 is 
unable to induce significant cytokine production. 
α-GalCer: The supernatants from PBMCs were stimulated with α-GalCer and then investigated 
for cytokine production. As previously reported9, -GalCer significantly increased the levels of 
IFN-γ beyond the levels found in unstimulated cultures in 4 of 7 HS (p=0.02). When levels of 
other cytokines were measured, IL-6 (p=0.008), IL-2 (p=0.03), and TNF-α (p=0.03) levels were 
all significantly upregulated upon stimulation with -GalCer in HS (ranging from 3-6 of 7 
subjects). Unlike FMC-7, -GalCer failed to increase significantly the levels of IL-17 although 
some increases were found in cultures from 10 of 15 subjects studied. Likewise while -GalCer 
stimulation increased levels of IL-4, IL-5, IL-10 and IL-12 production by PBMC from HS 
(ranging from 2-5 of 7 individuals), the levels failed to reach significance. Therefore -GalCer 
enhances cytokines associated with Th1 (IFN-γ) and pro-inflammatory (TNF-α, IL-6) responses 
predominantly. 
Cytokine levels were studied in MS PBMC cultures and the results compared with HS 
(Figure 3). As shown, the levels of TNF-α were significantly increased in cultures from 4 of 5 
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MS subjects (p=0.03) beyond unstimulated levels. Previously, we reported that stimulation of 
PBMC with -GalCer did not have a significant effect upon IFN-γ production.9 We extend these 
findings here and demonstrate that -GalCer also failed to increase levels of IL-2, IL-4, IL-5, IL-
6, IL-1 , IL10 or IL-12 beyond levels in unstimulated cultures. Although some increases in IL-
10 and IL-17 levels were found in 2 of 5 and 6 of 8 subjects respectively following stimulation 
with FMC-7, the results were not significant. There were no increases in cytokine levels 
observed upon stimulation with PA-GC in the MS subject group. Therefore, with the exception 
of TNF-, PBMCs from MS subjects failed to respond to stimulation with -GalCer, PA-GC or 
FMC-7 consistent with a state of anergy. 
 
 
DISCUSSION 
Regulatory roles for many lymphocyte populations14,15 have previously been reported for the 
suppression of disease development or prevention of MS. Previously, we reported altered 
numbers of T-cells bearing NK receptors (CD56+ T-cells and CD161+ T-cells) and including the 
iNKT-cells in the peripheral blood of MS patients.9  iNKT-cells are considered to be innate 
lymphocytes, possessing TCRs of limited diversity1,2 which are activated by glycolipids 
presented by the CD1d molecule.3 Despite the fact that the myelin sheath is made up of 
approximately 70% lipids and glycolipids, research into reactivity of human immune cells to the 
myelin-derived glycolipids has been neglected.16 To address this, we examined the stimulatory 
effects of a novel group of polyacetylated-β-galactosylceramides (PA-GC and purified FMC-7) 
that are endogenous and myelin-specific lipids11upon human peripheral blood derived iNKT-
cells, by examining cell expansion and cytokine production in both MS patients and HS. Overall 
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this study indicates that the numbers of iNKT-cells significantly expand upon stimulation with 
PA-GC, FMC-7 and α-GalCer in HS accompanied by robust cytokine secretion including IL-17. 
Importantly iNKT-cells from MS patients failed to respond to stimulation with PA-GC, FMC-7 
or α-GalCer consistent with a state of anergy that may be induced by prior exposure to antigens 
eliciting innate immune responses and including lipids and glycolipids.  
 In agreement with others17 iNKT-cell numbers are low in the peripheral blood of HS, but 
despite the low frequency, iNKT-cells significantly expand in number following stimulation with 
α-GalCer. While α-GalCer, a marine sponge derived glycolipid, is a known and potent activator 
of iNKT-cells5, other glycolipids and phospholipids also activate iNKT-cells including the 
mammalian lipids phosphatidylethanolamine18, isoglobotrihexosylceramide (iGb3)19,20 and 
ganglioside GD321 in addition to bacterial glycolipids.21-24 Recently, Brennan et al.25 reported 
that β-D-glucopyranosylceramide is a potent iNKT-cell self-antigen during microbial infection in 
mice and humans though it was much less potent than α-GalCer. Our myelin derived 
polyacetylated -galactosyl-ceramides can now be included amongst the stimulatory iNKT-cell 
activators in humans. The PA-GC (which is a mixture of FMC-5 and FMC-7)11-13 and in 
particular, the purified FMC-7 were stimulatory and in these studies expanded iNKT cell 
numbers as potently as α-GalCer. FMC-7 is an endogenous mammalian and CNS derived acetyl-
glycolipid that contrasts in its structure from -GalCer by having a -linked galactose rather than 
-linked galactose bound to ceramide. From our molecular modelling the acetylation modifies 
the conformation of the galactosylceramide that is characterized by free rotation of the galactose 
about the C-1 of ceramide by hydrogen bridge formation between the acetylated 3-OH-
sphingosine and the acetylated 2-OH-galactosyl and this may constrain the C-1 rotation. We 
propose that this alters the conformation of the polyacetylated FMC-7 acetyl-galactose head-
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group to fit the iTCR and then initiates the activation of the iNKT-cell: a speculation consistent 
with current concepts of ‘glycolipid moulding’ in the CD1-glycolipid-iTCR synapse that stem 
from x-ray crystallization studies.26 Importantly, in our study the glycolipid response as 
measured by an expansion in cell number was specific to the iNKT-cell population: there were 
no increases in the frequencies of either NK cells or NKR+ T-cells (CD56+ T-cells, CD161+ T-
cells and CD94+T-cells) upon stimulation with any of the glycolipids tested. 
In addition to the expansion in the numbers of iNKT-cells, the striking immuno-
stimulation by FMC-7 also induced production of a broad range of cytokines. These included 
cytokines associated with Th1 cells (IFN-γ), Th17 cells (IL-17, TNF-α) and both pro-
inflammatory (IL-1β, IL-6, TNF-α) and anti-inflammatory responses (IL-10). While the 
cytokines produced by PBMCs upon stimulation with α-GalCer induced a similar cytokine 
response to FMC-7, α-GalCer failed to increase IL-17 levels beyond those in unstimulated 
cultures. IL-17 is a pro-inflammatory cytokine that plays an important role in many autoimmune 
diseases.27 Moreover, IL-17 is upregulated in expression and involved in the pathogenesis of MS 
in humans28 and also in the animal disease model, experimental autoimmune encephalitis.29  
Excess production of IL-17 by auto-reactive Th17 cells in MS has been linked with disruption of 
tight junction proteins amongst the CNS endothelial cells.30 
When MS patients were investigated, iNKT-cells failed to expand in response to 
stimulation with either PA-GC or FMC-7. These findings extend our study here and in a previous 
report9 showing a lack of response to stimulation with -GalCer. In marked contrast to HS, while 
there was some TNF-α produced in response to stimulation, circulating lymphocytes from MS 
patients failed to produce a broad range of cytokines in response to either PA-GC or FMC-7 or to 
-GalCer. The results suggest that some functions of circulating lymphocytes including iNKT-
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cells are impaired in MS indicating a hypo-responsiveness in vitro. It resembles the reported T-
cell anergy in MS in remission31 with poor proliferative capacity that was broken with CD28 
stimulation while regulatory T cells had unaltered suppressive function except for lower IL-7 
receptors (CD127). Anergy amongst iNKT-cell populations has previously been demonstrated in 
mice employing repeated injections of -GalCer that induces unresponsiveness to re-stimulation 
in vivo or in vitro.32 Similar to our findings in MS, impaired proliferation and cytokine responses 
have previously been reported in patients with advanced cancers.33,34 While the exact molecular 
mechanisms which render iNKT-cells anergic remain to be elucidated, there is evidence that PD-
L1 signalling in combination with TCR signalling may contribute35,36 resulting in halting the 
immuno-regulatory functions of iNKT-cells. Others have shown that -GalCer-induced 
tolerance does not depend on Kupffer cells, IL-10, caspase-3-mediated apoptosis, or T regulatory 
cells in liver injury in mice.37 
NKT-cells play significant roles in maintaining peripheral tolerance and in protection 
against development of autoimmunity and in many other diseases including cancers and 
infection.38 They exert their immuno-regulatory functions through release of cytokines, 
activation of immune cells and induction of cytolytic activities.39 Many studies have investigated 
the nature of physiologically relevant self-lipid antigens for iNKT-cells and these include 
iGb319,20 and in microbial infection β-glucosyl-ceramide.25These lipid antigens however are not 
present at many sites where iNKT-cells accumulate and therefore it is difficult to appreciate fully 
their role in immunity. Previously, we reported that the mammalian myelin derived GSL tested 
here account for 15-35% of total myelin-derived GSL content.11 Moreover, the concentrations of 
these GSLs are altered in such demyelinating disease as MS.11 There exists the possibility that 
these myelin derived GSLs may contribute to iNKT-cell autoreactivity in MS in ways similar to 
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that of another lipid self-antigen, β-glucosylceramide during microbial infection.25 In MS, the 
continuing destruction of the myelin sheath may increase the expression of myelin-derived lipids 
in context of CD1d inducing inactivation or anergy of NKT-cells through mechanisms yet to be 
explored.  
In conclusion, the present study shows that circulating lymphocytes including iNKT-cells 
significantly expand upon stimulation with two myelin derived glycolipids, PA-GC and FMC-7 
as well as α-GalCer in HS. This is accompanied by robust cytokine secretion including IL-17 
driven in particular by FMC-7. Importantly iNKT-cells from MS patients failed to respond to 
glycolipid stimulation suggestive of a state of anergy. Rendering iNKT-cells hyporesponsive to 
an endogenous glycolipid is a novel insight into diseases manifesting aberrant iNKT-cell 
activation and consequently this finding of glycolipid ligand-driven anergy in MS has substantial 
implications for MS immunotherapy. 
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Figure 1. Structures of the different glycolipids used in this study. 
Diagram represents the structures of (A) α-galactosylceramide (α-GalCer) and (B) the myelin-
derived glycolipids, the fast migrating cerebrosides (FMC) as determined by mass spectrometry. 
In B, the structure shows where the R groups are positioned to give rise to either β-GalCer, 
FMC-5 or FMC-7.  Adapted from Podbielska et al13. 
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Figure 2. iNKT-cells are expanded in number after stimulation with myelin-derived 
glycolipids.  
PBMCs were stimulated for seven days with the poly-acetylayed myelin-derived glycolipids 
(PA-GC) or with purified FMC-7 or α-GalCer. The % of iNKT-cells were then quantified by 
flow cytometry and results compared with unstimulated cell cultures. In A, XY scatter plots 
show the % of iNKT-cells from healthy control subjects (HS) and multiple sclerosis (MS) 
samples. Horizontal bars indicate median values. B, Representative flow cytometric dot plots 
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showing iNKT-cells from representative HS and MS subjects. Lymphocytes were set on the 
basis of cells size and granularirty (FSC/SSC) and quadrants were set using isotype-matched 
control antibodies. The percentages of CD3+ T cells expressing the invariant Vα24-Jα18+ T-cell 
receptor are shown in the upper right quadrant. p values; * =  0.0491; ** = 0.0205; *** = 0.0045. 
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Figure 3. Cytokine production by peripheral blood mononuclear cells is impaired in 
patients with multiple sclerosis following stimulation by glycolipids. 
 
PBMCs from healthy control subjects (HS) or multiple sclerosis patients (MS) were stimulated 
with the poly-acetylated myelin-derived glycolipids (PA-GC), purified FMC-7 or α-GalCer for 
168 hrs. The levels of IFN-γ, IL-1β, IL-2, IL-6, IL-10, IL-17, TNF-α and IL-4 in culture 
supernatants were measured using the FlowCytomix multiplex kit. The line graphs show the 
cytokine levels in unstimulated cell cultures (unstim), or in PA-GC, FMC-7 or α-GalCer 
stimulated cultures. p values are shown. 
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Table 1. Lack of expansion of NK and NKR
+
 T-Cells from Healthy Subjects and Multiple Sclerosis Subjects after glycolipid  stimulation  
   
HEALTHY SUBJECTS  
  
MULTIPLE SCLEROSIS SUBJECTS 
 
  
 
Unstim %  PA-GC %  FMC-7 %  α-GalCer %  
 
Unstim %  PA-GC %  FMC-7 %  α-GalCer %  
NK-cell           
CD56
+
CD3
-
 
Median  
(range) 
7.2  
(1.18-14.62) 
4.9 
(0.92-10.29) 
8.7 
(2.12-15.26) 
8.4 
(1.72-14.49) 
 3.2  
(0.58-17.4) 
3.5  
(1.44-17.63) 
7.0  
(0.89-14.01) 
3.9  
(0.33-6.76) 
 n =  11 7 8 11  8 4 5 8 
           
NKR
+
 T-cells           
CD56
+
CD3
+
 
Median  
(range) 
4.3 
(2.1-11.58) 
5.6 
(1.55-8.06) 
4.9 
(1.57-17.06) 
6.7 
(0.77-12.9) 
 4.9  
(0.88-12.75) 
4.5 
(1.31-16.3)  
2.6 
(0.01-11.14) 
4.7  
(1.73-18.62) 
 n =  12 7 8 11  12 4 6 12 
           
CD161
+
CD3
+
 
Median  
(range) 
7.3 
(3.71-20.48) 
11.4 
(3.23-19.71)   
13.7 
(1.95-31.07)  
11.1  
(2.75-25.14) 
 7.9  
(1.92-10.56) 
8.2  
(6.34-12.57) 
7.1  
(1.27-23.56) 
8.1  
(2.61-10.29) 
 n =  12 7 8 11  12 4 6 12 
           
CD94
+
CD3
+
 
Median  
(range) 
4.6 
(1.02-10.51) 
2.4  
(1.67-9.72) 
6.5  
(1.35-20.95) 
6.9 
(1.42-13.09) 
 3.2  
(1.58-6.24) 
1.1  
(1.01-8.01) 
3.8  
(0.75-7.63) 
2.6 
(1.78-6.23)  
 n =  7 7 7 7  3 3 3 3 
Data shows % of Natural Killer (NK) cells and Natural Killer Receptor
+ 
T-cells (NKR
+ 
T-cells) amongst cultured PBMC after stimulation with polyacetylated 
galactocylceramide (PA-GC), purified FMC-7 or -GalCer compared with unstimulated cells. n = sample size.  
 
 
 
 
 
 
 
 
